Zur Identifízierung von Neuroblastomzellen aus Knochenmark von 12 Kindern in verschiedenen Krankheitsstadien wurde das immuno-alkalische Phosphatase-Verfahren (APAAP) eingesetzt. Unter Verwen-dung eines Panels monoklonaler Antikörper, die sich selektiv an Zellen neuroektodermalen Ursprungs anbinden, wurden 72 immunologische Analysen durchgeführt. Hierbei wurden 57 × Tumorzellen identifiziert, wohingegen histologische und zytologische Analysen in 45 beziehungsweise 37 Fallen pathologische Zellen zeigten. Die Reaktivität kleinster Resttumorzellen – in der Hauptsache mit den drei monoklonalen Antikörpern UJ13A, UJ167.11, A2B5 – weist darauf hin. daß diese Zellen zu einem resistenten Neuroblastomzellklon gehören, der trotz intensiver Therapie im Knochenmark verbleibt. Unsere Studie zeigt, daß das immunologische Anfärben zur Identifikation und Definition einer geringen Anzahl von Neuroblastomzellen dienen kann, die unter Zuhilfenahme traditioneller histologischer und zytologischer Kriterien noch nicht zu entdecken sind.

Keywords:
Neuroblastom-Resttumorzellen, Immunphänotypierung, Monoklonale Antikörper
This content is only available via PDF.
© 1989 S. Karger AG, Basel
1989
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.